Department of Nutritional Sciences, King's College London, London, UK.
Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK; Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1147-1161. doi: 10.1016/S2468-1253(24)00238-3.
Diet is a cornerstone in the management of irritable bowel syndrome (IBS). There is evidence of efficacy across the spectrum of dietary management strategies, including some supplements (eg, specific fibres), foods, and whole diets (eg, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols [known as the low-FODMAP diet]). Whole-diet interventions, in particular those that restrict intake, can be challenging to deliver effectively and safely. Factors to consider include patient demographics, food cost and availability, and the acceptability of dietary management and its impact on food-related quality of life. There is concern regarding a potential role of restrictive whole-diet interventions in eating disorder risk. Optimal approaches to delivering dietary management in the health-care setting are unclear. The aim of this Review is to summarise the clinical evidence for the dietary management of IBS; to discuss the challenges, burdens, and risks of dietary management; and to propose how these challenges, burdens, and risks should be mitigated and minimised in clinical practice.
饮食是肠易激综合征(IBS)管理的基石。有证据表明,各种饮食管理策略都具有疗效,包括一些补充剂(例如特定纤维)、食物和全饮食(例如低可发酵寡糖、双糖、单糖和多元醇饮食[简称低 FODMAP 饮食])。全饮食干预,特别是那些限制摄入的干预,在有效和安全实施方面可能具有挑战性。需要考虑的因素包括患者人口统计学特征、食物成本和可获得性,以及饮食管理的可接受性及其对与食物相关的生活质量的影响。人们担心限制全饮食干预可能会增加饮食失调的风险。在医疗保健环境中实施饮食管理的最佳方法尚不清楚。本综述旨在总结 IBS 饮食管理的临床证据;讨论饮食管理的挑战、负担和风险;并提出如何在临床实践中减轻和最小化这些挑战、负担和风险。
Lancet Gastroenterol Hepatol. 2024-12
Cochrane Database Syst Rev. 2017-3-23
Korean J Gastroenterol. 2022-7-25
Aliment Pharmacol Ther. 2017-4-25
Clin Gastroenterol Hepatol. 2025-2